ENLV
Enlivex Therapeutics LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$195.28M
P/E Ratio
0.03
EPS
$24.91
Beta
1.68
52W High
$2.10
52W Low
$0.66
50-Day MA
$1.06
200-Day MA
$1.08
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd. is a clinical stage immunotherapy company. The company is headquartered in Nes Ziona, Israel.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-14.67M |
| Operating Margin | 0.00% |
| Return on Equity | 126.20% |
| Return on Assets | -0.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $8.15 |
| Price-to-Book | 0.10 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.49 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $239.32M |
| Float | $54.94M |
| % Insiders | 0.46% |
| % Institutions | 0.82% |
Historical Volatility
HV 10-Day
110.73%
HV 20-Day
111.54%
HV 30-Day
97.25%
HV 60-Day
84.76%
HV Rank
86.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($20.00 target)
1
Buy1
HoldData last updated: 4/15/2026